We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 29. | 장 마감 후 (AMC) | $0.61 | — | — | $1.29B | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.27 | — | — | $1.04B | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $1.04 | — | — | $2.92B |
Consensus PT $82.04 · 25 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Citigroup | — | 의견 유지 | Buy → Buy | — | Citigroup: Buy |
| 2026. 05. 19. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $0.71 | — | — | $1.93B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,217,607 | $80.81B | 0.13% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,082,913 | $71.87B | 0.11% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
How Investors May Respond To DexCom (DXCM) Global App Recalls Over Delayed Glucose Alerts - simplywall.st
How Investors May Respond To DexCom (DXCM) Global App Recalls Over Delayed Glucose Alerts simplywall.st
Scrapped CGM sensors stolen, sold to patients—Dexcom pledges to hold thieves accountable - Cardiovascular Business
Scrapped CGM sensors stolen, sold to patients—Dexcom pledges to hold thieves accountable Cardiovascular Business
Dexcom Discovers Theft of Scrapped G7 CGM Sensors - Medical Product Outsourcing
Dexcom Discovers Theft of Scrapped G7 CGM Sensors Medical Product Outsourcing
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets - Yahoo Finance
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets Yahoo Finance
Signos raises $20M, expands Dexcom partnership for weight loss - qz.com
Signos raises $20M, expands Dexcom partnership for weight loss qz.com